Disc Medicine, Inc.

IRONSEC EDGAR

Pharmaceutical PreparationsCIK: 1816736

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$69.3M	$69.3M	$33.4M	$25.2M	$28.2M
Selling, General and Administrative Expense	$21.9M	$21.9M	—	—	—
Operating Expenses	$91.1M	$91.1M	$47.5M	$30.9M	$34.0M
Operating Income (Loss)	-$91.1M	-$91.1M	-$47.5M	-$30.9M	-$34.0M
Interest Expense	—	—	—	—	$6.8M
Nonoperating Income (Expense)	$14.8M	$14.8M	$648.0K	-$5.0M	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$76.3M	-$76.3M	-$46.8M	—	—
Income Tax Expense (Benefit)	$99.0K	$99.0K	$0.00	—	—
Net Income (Loss) Attributable to Parent	-$76.4M	-$76.4M	-$46.8M	-$36.0M	-$40.8M
Earnings Per Share, Basic	-$3.42	-$3.42	-$45.05	-$40.95	—
Earnings Per Share, Diluted	-$3.42	-$3.42	-$45.05	-$40.95	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$496.8M	$368.0M	$200.2M	$92.4M	$8.3M
Assets, Current	$493.6M	$365.7M	$198.5M	$90.5M	$5.1M
Cash and Cash Equivalents, at Carrying Value	$192.4M	$360.4M	$194.6M	$88.0M	$4.5M
Liabilities	$53.2M	$22.9M	$23.6M	$14.8M	$30.2M
Liabilities, Current	$23.3M	$21.4M	$22.6M	$13.4M	$24.9M
Long-term Debt	$28.3M	$0.00	—	—	$14.0M
Accounts Payable, Current	$7.9M	$12.6M	$16.2M	$2.6M	$2.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$73.5M	-$73.5M	-$42.3M	-$27.5M	-$32.7M
Net Cash Provided by (Used in) Investing Activities	-$89.0K	-$89.0K	-$151.0K	-$68.0K	-$22.0K
Net Cash Provided by (Used in) Financing Activities	$239.4M	$239.4M	$149.0M	$89.9M	$34.2M
Payments to Acquire Property, Plant, and Equipment	$89.0K	$89.0K	$151.0K	$68.0K	$22.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)